PHATHOM PHARMACEUTICALS INC (PHAT) Forecast, Price Target & Analyst Ratings
NASDAQ:PHAT • US71722W1071
10.67 USD
-0.07 (-0.65%)
At close: Mar 6, 2026
10.67 USD
0 (0%)
After Hours: 3/6/2026, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHATHOM PHARMACEUTICALS INC (PHAT).
Forecast Snapshot
Consensus Price Target
$23.36
+ 118.91% Upside
Next Earnings Forecast
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate-$0.36
Revenue Estimate60.175M
ChartMill Buy Consensus
83.53%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$23.36
Upside
+ 118.91%
From current price of $10.67 to mean target of $23.36, Based on 17 analyst forecasts
Low
$12.12
Median
$24.48
High
$30.45
Price Target Revisions
1 Month
0.00%
3 Months
1.78%
Price Target Summary
17 analysts have analysed PHAT and the average price target is 23.36 USD. This implies a price increase of 118.91% is expected in the next year compared to the current price of 10.67.
The average price target has been revised upward by 1.78% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.53%
PHAT was analyzed by 17 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about PHAT.
In the previous month the buy percentage consensus was at a similar level.
PHAT was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-27 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Equal-Weight |
| 2025-10-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-09 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-06-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-06 | Needham | Maintains | Buy -> Buy |
| 2025-05-02 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-02 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-21 | Needham | Reiterate | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-04-02 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-02 | Needham | Reiterate | Buy -> Buy |
| 2025-03-10 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-06 | Needham | Reiterate | Buy -> Buy |
| 2025-01-10 | Needham | Reiterate | Buy -> Buy |
| 2024-12-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | Needham | Reiterate | Buy -> Buy |
| 2024-09-13 | Needham | Reiterate | Buy -> Buy |
| 2024-09-06 | Needham | Reiterate | Buy -> Buy |
| 2024-08-30 | Needham | Reiterate | Buy -> Buy |
| 2024-08-23 | Needham | Reiterate | Buy -> Buy |
| 2024-08-19 | Needham | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate-$0.36
Revenue Estimate60.175M
Revenue Q2Q111.00%
EPS Q2Q72.75%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
0.40%
Revenue (3 Months)
2.16%
EPS (1 Month)
0.74%
EPS (3 Months)
-5.46%
Next Earnings Summary
PHAT is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is -0.36 USD and the consensus revenue estimate is 60.17M USD.
The next earnings revenue estimate has been revised upward by 2.16% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 682K | 55.252M 8,001.47% | 177.84M 221.87% | 335.55M 88.68% | 536.26M 59.82% | 768.54M 43.31% | 909.46M 18.34% | 1.037B 14.02% | 1.181B 13.89% | 1.278B 8.21% | 892.16M -30.19% | ||
| EBITDA YoY % growth | -171.82M -27.69% | -166.737M 2.96% | -276.672M -65.93% | -152.028M 45.05% | 30.786M 120.25% | 135.26M 339.36% | 360.03M 166.18% | 481.59M 33.76% | 587.39M 21.97% | 679.94M 15.76% | 756.12M 11.20% | N/A | |
| EBIT YoY % growth | -172.44M -27.66% | -167.312M 2.97% | -277.467M -65.84% | -166.714M 39.92% | -425.677K 99.74% | 163.26M 38,453.06% | 345.96M 111.91% | 451.92M 30.63% | 546.52M 20.93% | 665.2M 21.72% | 734.57M 10.43% | 476.62M -35.12% | |
| Operating Margin | N/A | -24,532.55% | -502.18% | -93.74% | -0.13% | 30.44% | 45.02% | 49.69% | 52.70% | 56.33% | 57.48% | 53.42% | |
| EPS YoY % growth | -5.05 -29.82% | -3.88 23.17% | -5.35 -37.89% | -3.25 42.80% | -0.82 73.14% | 1.10 233.33% | 3.10 182.82% | 4.47 44.38% | 5.65 26.29% | 7.43 31.50% | 8.47 14.00% | 7.99 -5.72% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.36 72.75% | -0.26 75.16% | -0.19 53.56% | -0.05 83.82% | -0.14 60.00% | 0.08 131.29% | 0.27 239.28% | 0.48 1,121.74% |
| Revenue Q2Q % growth | 60.175M 111.00% | 76.134M 92.73% | 87.676M 77.11% | 101.78M 76.78% | 89.454M 48.66% | 108.73M 42.81% | 125.05M 42.63% | 143.62M 41.11% |
| EBITDA Q2Q % growth | -10.071M 87.20% | -29.58K 99.95% | 13.405M 190.78% | 16.932M 445.55% | 3.876M 138.48% | 15.402M 52,168.97% | 23.154M 72.73% | 31.008M 83.13% |
| EBIT Q2Q % growth | -12.738M 83.85% | -5.084M 91.52% | 5.176M 133.89% | 12.96M 218.33% | 6.528M 151.25% | 23.358M 559.46% | 37.128M 617.31% | 52.836M 307.69% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
44.43%
EPS Next 5 Year
30.92%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
62.88%
Revenue Next 5 Year
42.28%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
35.01%
EBIT Next 5 Year
29.49%
PHATHOM PHARMACEUTICALS INC / PHAT Forecast FAQ
What is the price target for PHAT stock?
17 analysts have analysed PHAT and the average price target is 23.36 USD. This implies a price increase of 118.91% is expected in the next year compared to the current price of 10.67.
When does PHATHOM PHARMACEUTICALS INC (PHAT) report earnings?
PHATHOM PHARMACEUTICALS INC (PHAT) will report earnings on 2026-04-29.
What are the consensus estimates for PHATHOM PHARMACEUTICALS INC (PHAT) next earnings?
The consensus EPS estimate for the next earnings of PHATHOM PHARMACEUTICALS INC (PHAT) is -0.36 USD and the consensus revenue estimate is 60.17M USD.
What is the consensus rating for PHAT stock?
The consensus rating for PHATHOM PHARMACEUTICALS INC (PHAT) is 83.5294 / 100 . This indicates that analysts generally have a positive outlook on the stock.